NeurAxon Pharmaceuticals

NeurAxon was a clinical-stage biopharmaceutical company focused on developing innovative therapies for pain and neurological disorders by targeting neuronal nitric oxide synthase (nNOS). The company's lead program, NXN-188, was a novel dual-action small molecule designed to treat migraine by combining nNOS inhibition with serotonin receptor agonism. Beyond migraine, NeurAxon explored nNOS inhibitors for neuropathic pain and other chronic pain conditions. In 2014, the company's intellectual property and nNOS-related assets were acquired by Xenon Pharmaceuticals. This acquisition integrated NeurAxon's specialized pain research into Xenon's broader neurology pipeline.